Summit Therapeutics Inc. (SMMT) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Cambridge, MA, United States. Le PDG actuel est Robert W. Duggan.
SMMT a date d'introduction en bourse 2015-03-05, 159 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $15.52B.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to treat infectious diseases in the United States and Latin America. The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials for Clostridioides difficile infection (CDI). Summit's pipeline also includes SMT-738, designed to address multidrug-resistant infections such as carbapenem-resistant Enterobacteriaceae, and the DDS-04 series for treating Enterobacteriaceae infections. Founded in 2003 and headquartered in Cambridge, Massachusetts, the company is advancing its clinical programs to address critical unmet needs in infectious disease treatment.
